In a study involving 32 patients with NSCLC who experienced purpuric drug eruptions due to EGFR-TKIs (gefitinib, erlotinib, and afatinib), the predominant characteristics of these eruptions were observed to be purpuric papules, pustules, or confluent plaques on the lower limbs. Here, EGFR is linked to non-small cell lung carcinoma.